Dr Maryam Parviz is the co-founder and CEO at "SDIP Innovations" with more than 12 years' experience in the Biomaterial field. She received BSc and MSc degree in Biomedical Engineering from Tehran Polytechnic. Maryam received her PhD on implantable electrodes from the University of New South Wales in Australia sponsored by one of the most prestigious Australian scholarships, UIPA. She has been trained on commercialisation of medical devices and worked with medical device startups on research translation before founding SDIP in 2018. Since then Maryam has contributed in securing angel and grant investments, development of new JAZBI`s formula and designs, the establishment of the company QA system and the formation of the expert team on the business and clinical sides who can take JAZBI products to surgeon`s hand. In 2019, Maryam and her co-founder were awarded $1M (AUD) by NSW Health- QB3/UCSF Rosenman to operate SDIP Innovations from San Francisco with the vision of providing improved patient outcomes globally and reserving the hospital capacities for emergencies and essential operations.
Dr Iman Manavitehrani is the co-founder and CSO at SDIP. He is an engineer,entrepreneur and the inventor of JAZBI technology. Iman did his PhD in Biomolecular Engineering at The University of Sydney from 2013-2016. He further developed his skills during his employment at the Children Hospital at Westmead as a biomaterial scientist prior to funding SDIP in 2018. With his background in BSc and MSc in biomedical and tissue engineering and drug delivery, Iman is the inventor in 5 patents. Iman and his co-founder have been awarded $1M NSW health- QB3/UCSF Rosenman fellowship and were given the facilities to operate SDIP Innovations from San Francisco. Iman spends his time on manufacturing as well as SDIP's research and development to further adopt the JAZBI™ implants technology into other markets.
Fred Dinger has over 25 years of experience with both large and small medical device companies. Prior to Aerin Medical, Fred served as President and Chief Executive Officer at ENTrigue Surgical, C2M Medical and OsteoBiologics Inc (OBI), and has held leadership positions with A-Med Systems, where he served as Vice President and Chief Operating Officer, as well as Linvatec Corporation and Xomed Surgical Products that all have been acquired by large corporations. Fred earned a Bachelor of Science in Mechanical Engineering from Cornell University and a Master of Science in Engineering Management from the University of South Florida. Fred and another three ex-members of Osteobiologics join SDIP as they are so passionate about providing improved bone implants for patients around the globe.
Mrs Scott has more than 15 years of experience in regulatory management and quality assurance expert in filling De Nova, 510k, and Q-Sub and EU applications. She received a Master of Science in Regulatory Affairs for Medical Devices, Drugs, and Biologics from Northeastern University and a Bachelor of Science in Biochemistry from Texas M&A University in 1991. Shannon is also Manager Regulatory Affairs at 3M, and previously she has served as Director of Regulatory at Smith and Nephew and OsteoBiologics Inc(OBI) (2003-2010).
Dr. Niederauer has more than 25 years of experience in the study, development, and commercialization of devices for orthopedic, dental, and ENT. Previously, Dr. Niederauer led R&D at ENTrigue Surgical, Inc., which was acquired by ArthroCare Corporation by Smith&Nephew in 2014. Dr. Niederauer served as Vice President of Research & Development at C2M Medical, developing and commercializing the Cinch/Piton shoulder anchor, acquired by Tornier, Inc. in 2010. Prior to that, she was Director of R&D at OsteoBiologics, Inc. (OBI), launching a dozen new products in cartilage/bone repair. OBI was acquired by Smith& Nephew, Inc in 2006.
Dr. Niederauer completed a Post-Doctoral Fellowship at the Orthopaedic Biomechanics Laboratory at UTHSCSA and earned her degree in Biomedical Engineering from Iowa State University, Masters of Science in Materials Science and Biomedical Engineering from Iowa State University, and a Bachelor of Science degree in Ceramic Engineering from Clemson University.
Dr. Niederauer has more than 25 years of experience in the research, development, and commercialization of biologics, pharmaceuticals, and medical devices. He has developed and implemented quality systems, established, validated, and scaled-up manufacturing operations, developed and launched medical devices, and obtained regulatory approvals. Previously, Dr. Mark Niederauer was the Plant Manager at Smith & Nephew, which developed and manufactured resorbable implants for the repair of bone and cartilage. Prior to that he was with OsteoBiologics, Inc. (OBI), where he served as Director of Operations managing the facility certification to ISO 9001/EN 460001 and later ISO 13485, and the receipt of the first CE Mark in the world for a resorbable cartilage repair implant. OBI was acquired by Smith & Nephew for $72.3 million. Prior to OBI, Dr. Mark Niederauer managed the development and manufacturing at Hoechst Celanese, in TX, and for Bayer Chemikalien in Germany.
Dr. Mark Niederauer completed a Post-Doctoral Fellowship and earned a Doctor of Philosophy degree in Biochemical Engineering from Iowa State University. He is a Fulbright Scholar, earning the equivalent of a Master of Science degree in Environmental Engineering at the Universität Stuttgart in Germany. He earned a Bachelor of Science degree in Chemical Engineering from Clemson University.
Brett is an orthopaedic surgeon in Sydney, Australia, specialising in knee surgery. He is a teaching surgeon at Royal Prince Alfred Hospital (affiliated with the University of Sydney), and a member of the Australian Orthopaedic Association, The Australian Knee Society and the International Society of Arthroscopy, Knee Surgery and Orthopaedic Sports medicine (ISAKOS). He is the director of the Sydney Orthopaedic Research Institute (SORI).
Dr. Mohammad Diab is an orthopedic surgeon and chief of pediatric orthopedics at UCSF Benioff Children's Hospital. He specializes in treating musculoskeletal conditions in children and teenagers, and residual childhood deformities in young adults. Diab earned his medical degree from Stanford University. He completed a residency in general orthopedic surgery at the University of Washington and a fellowship in pediatric orthopedic surgery at Harvard University. He came to UCSF in 2002. Diab is a member of the American Academy of Orthopaedic Surgeons, American Academy of Pediatrics, American Medical Association, Pediatric Orthopaedic Society of North America and Scoliosis Research Society. He held an Academy of Medical Educators chair at UCSF for a decade and now holds the endowed chair in pediatric orthopedic education. Born in Cairo, Diab completed his early education in the United Kingdom. Rooted in his undergraduate major of classical studies and spurred by his interest in the history of medicine, he is the writer of Lexicon of Orthopædic Etymology book.
Dr. Jabbarzadeh is a Venture Capital Partner at IAG Capital Partners, an early-stage investment firm specializing in life sciences and advanced computing startups. He also holds a position of Full Professor of Chemical and Biological Engineering and Director of Engineering Entrepreneurship at the University of South Carolina. His professional career is represented by a Venn diagram of innovation,entrepreneurship, and academic leadership. As an innovator, directed a federally funded research laboratory focusing on biomaterials and stem cells. As an entrepreneur, he co-founded and led Obsidio Inc, a venture backed medical device company that pioneered a biomaterial technology with applications in hemorrhage control and interventional oncology. Obsidio was launched in 2019, received FDA clearance in July 2022, and was acquired by Boston Scientific in August 2022. As an academic leader, he oversaw the National Science Foundation (NSF) funded I-Corps as well as the Technology Innovation and Entrepreneurial Engineering program. Dr. Jabbarzadeh’s credentials include a PhD in chemical engineering from Drexel University, Postdoctoral Fellowship in bioengineering from the California Institute of Technology, and an MBA in finance and entrepreneurship from the University of Southern California, MarshallSchool of Business.
Ben Write is Investment Manager at Nanosonics Ltd and managing director at Ballistic ventures. Previously Mr. Write was Chief Innovation Officer and Head of Investment Strategy at Cicada Innovations (2014-2019), Australia's largest deep technology incubator. He is an execution-focused professional with over 20 years’ experience in Research and Development, Clinical Trials, Operations, Financial Management and Commercialisation within both private and ASX listed technology businesses. Ben has served as an educator at CSIRO Lean Launchpad mentor, CSIRO On Accelerator, Medical Device Commercialisation Training course sponsored by NSW Health, Australia.
